Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 18,658 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adult Clear all
Suspended Phase 2 Interventional

Ascorbate in Myelodysplastic Syndrome

NCT07283900
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
High-dose ascorbate, Azacitidine
Drug
Lead sponsor
Prajwal Dhakal
Other
Eligibility
18 Years to 99 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

NCT00666588
View directory record Official record
Conditions
Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myelomonocytic Leukemia (M4), Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
idarubicin, cytarabine, bortezomib, etoposide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
77
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 72 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 28, 2026, 9:38 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome

NCT02153983
View directory record Official record
Conditions
Obesity, Metabolic Disease
Interventions
Colchicine 0.6Mg Cap, Placebo capsules given, Colchicine 0.6Mg Tab
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 100 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 28, 2026, 9:38 AM EDT
Completed No phase listed Observational

An Exploratory Study of the Use of Five Wishes as a Tool for Advanced Care Planning in Young Adults With Metastatic, Recurrent, or Progressive Cancer or HIV Infection

NCT01445145
View directory record Official record
Conditions
Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 30 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 28, 2026, 9:38 AM EDT
Not yet recruiting Not applicable Interventional

Development of a Power Training Program to Improve Mobility in Older Veterans

NCT07210645
View directory record Official record
Conditions
Physical Deconditioning, Mobility Decline
Interventions
Gerofit Power Training, Gerofit Standard of Care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 28, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I, Open Label,Crossover Food-Effect and Absolute Bioavailability Study of WCK2349 and WCK771 in Healthy Adult Human Volunteers

NCT01875939
View directory record Official record
Conditions
Effect of Food
Interventions
Oral WCK2349, IV WCK771
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 28, 2026, 9:38 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

NCT06665646
View directory record Official record
Conditions
HIV Infections
Interventions
CD40.HIVRI.Env (VRIPRO), Hiltonol Poly-ICLC-adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
7
States / cities
San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 28, 2026, 9:38 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults

NCT07888088
View directory record Official record
Conditions
Epstein Barr Virus (EBV) Infection
Interventions
MVA-BN-EBV, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 30 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

NCT02251288
View directory record Official record
Conditions
Avian Influenza, Immunisation
Interventions
Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59 adjuvant
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 47 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 28, 2026, 9:38 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Information Processing Biases in Adults Who Stutter

NCT06422442
View directory record Official record
Conditions
Stuttering, Adult
Interventions
Threat-related stimulus exposure
Behavioral
Lead sponsor
University of Memphis
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 28, 2026, 9:38 AM EDT
Terminated Phase 3 Interventional Results available

Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases

NCT00540969
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cryosurgery, radiation therapy
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 28, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)

NCT03779841
View directory record Official record
Conditions
Post-Operative Atrial Fibrillation
Interventions
AGN-151607, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 90 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
19
States / cities
Stanford, California • New Haven, Connecticut • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 28, 2026, 9:38 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Intervention to Address Psychosocial Needs Among Socially Disadvantaged Older Adults With Cancer

NCT05828654
View directory record Official record
Conditions
Hematological Disorder
Interventions
Focus Group Discussions and Semi-structured Interviews, Training community lay navigators
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 28, 2026, 9:38 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

NCT04370054
View directory record Official record
Conditions
Hemophilia A
Interventions
PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
19
States / cities
Mountain View, California • Oakland, California • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 28, 2026, 9:38 AM EDT
Completed Not applicable Interventional Results available

Mild Cognitive Impairment and Obstructive Sleep Apnea

NCT01482351
View directory record Official record
Conditions
Obstructive Sleep Apnea, Mild Cognitive Impairment
Interventions
CPAP adherence intervention, Attention control intervention
Behavioral
Lead sponsor
George Mason University
Other
Eligibility
55 Years to 89 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Abington, Pennsylvania • Philadelphia, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 28, 2026, 9:38 AM EDT
Active, not recruiting Phase 3 Interventional

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)

NCT06358651
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Fasedienol Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 28, 2026, 9:38 AM EDT
Completed No phase listed Observational

Restricted Useful Field View as a Risk Factor in Older Adults

NCT00013351
View directory record Official record
Conditions
Vision Impairment
Interventions
Prevention of Falls
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 28, 2026, 9:38 AM EDT
Terminated Phase 2 Interventional Results available

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

NCT04887831
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult, Chemotherapy-induced Neutropenia, Metastatic Bladder Cancer
Interventions
Trilaciclib, Gemcitabine, Cisplatin, Carboplatin, Avelumab
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Los Angeles, California • Whittier, California • Littleton, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 28, 2026, 9:38 AM EDT
Completed Not applicable Interventional

Improving Walking in Older Adults With Knee Osteoarthritis

NCT00583245
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Gait Training
Other
Lead sponsor
University of Iowa
Other
Eligibility
60 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 28, 2026, 9:38 AM EDT
Completed Phase 3 Interventional

PRC-063 in an ADULT Workplace Environment

NCT02225639
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
PRC-063 25 mg, Placebo, PRC-063 35 mg, PRC-063 45 mg, PRC-063 55 mg, PRC-063 70 mg, PRC-063 85 mg, PRC-063 100 mg
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Newport Beach, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 28, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants

NCT07588139
View directory record Official record
Conditions
Healthy Participants
Interventions
Povorcitinib, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 9:38 AM EDT
Recruiting Phase 1 Interventional

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

NCT06501196
View directory record Official record
Conditions
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia, Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia
Interventions
BH-30236, Venetoclax
Drug
Lead sponsor
BlossomHill Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 28, 2026, 9:38 AM EDT
Active, not recruiting Phase 2 Interventional

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

NCT03363373
View directory record Official record
Conditions
Neuroblastoma
Interventions
GM-CSF + Naxitamab
Biological
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
1 Year and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 28, 2026, 9:38 AM EDT
Suspended Phase 1 Interventional

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial

NCT04539366
View directory record Official record
Conditions
Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Childhood Neuroblastoma, Refractory Childhood Osteosarcoma, Refractory Neuroblastoma, Refractory Osteosarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Fludarabine Phosphate, GD2-CAR-expressing Autologous T-lymphocytes, Imaging Procedure, Magnetic Resonance Imaging of the Heart, Multigated Acquisition Scan, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 40 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
6
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 28, 2026, 9:38 AM EDT